ERYTECH Provides Business and Financial Update for the Third Quarter of 2021
Conference call and webcast on Tuesday, November 16, 2021 at 8:30am EST / 2:30pm CET Progress towards seeking approval of eryaspase for the treatment of ALL patients who experienced hypersensitivity…
ERYTECH Announces Upcoming Poster Presentation at the 2021 American Society of Hematology Annual Meeting
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the acceptance of an abstract with…
ERYTECH Announces Publication of a Paper on Red-Blood Cell Characterization in High Impact Peer Reviewed Journal
The Paper "Multiparametric characterization of red blood cell physiology after hypotonic dialysis based drug encapsulation process" is available in the October 2021 (Volume 11, Issue 10) of Acta Pharmaceutica Sinica…
ERYTECH to Present at the 12th Annual Jefferies Global London Healthcare Conference
In-Person Dates: November 16th-17th • Virtual Dates: November 18th-19th ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood…
ERYTECH Announces Results from TRYbeCA-1 Phase 3 Trial of Eryaspase in Patients with Second-line Advanced Pancreatic Cancer
Management to host Conference Call on Monday, October 25, at 8:30am EDT/ 2:30pm CEST ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic…
ERYTECH Announces Maximum Tolerated Dose Declared in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer
No dose-limiting toxicity (DLT) reported in first two dose cohorts, leading to declaration of the maximum tolerated dose (MTD) at 100 U/kgEncouraging clinical activity observed in first patients ERYTECH Pharma…
ERYTECH to Participate in the HealthTech Innovation Days (HTID) by France Biotech
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the company’s participation in one-on-one investor…
ERYTECH Announces the Availability of its Half-Year Financial Report 2021
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced that it had filed with the Autorité…
ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2021
Conference call and webcast on Tuesday, September 21, 2021 at 8:30am EDT / 2:30pm CET ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating…
- 1
- 2
- 3
- 4
- …
- 26
- Go to the next page